AUS
NZ
UK
CA
USA
IND
Highlights
- Emyria opens second mental health centre in Perth
- Fully funded patient treatments begin
- Plans aligned for national expansion
Emyria Ltd (ASX:EMD) is making significant strides in Australia’s mental health sector with the expansion of its psychedelic-assisted therapy services. The company has launched its second ‘Empax’ treatment centre within the highly regarded Perth Clinic, building on the success of its first location in Leederville, Western Australia.
This expansion comes at a critical time as the demand for advanced mental health care solutions grows across the country. Emyria’s new facility is designed to support individuals dealing with complex conditions such as post-traumatic stress disorder (PTSD) and treatment-resistant depression. The addition of this new centre is expected to increase the company’s capacity to deliver its specialised therapy programs by 50%.
A key milestone in this expansion is the commencement of treatment for the first two fully funded patients at the Perth Clinic site on April 14th. This event not only activates the new facility but also reflects the company's broader strategy to integrate its services with evolving healthcare funding models in Australia. By aligning its offerings with financial support systems, Emyria is helping remove barriers to access for patients who may benefit from these innovative therapies.
The Empax centre’s integration within a licensed hospital is a strategic move that positions the company well for further growth. This setup supports funding eligibility and ensures that treatment protocols meet rigorous regulatory standards, enhancing patient trust and treatment outcomes. Moreover, it paves the way for potential expansion into Australia’s eastern states, broadening the company’s reach to more communities in need.
Greg Hutchinson, Executive Chair of Emyria, emphasized the importance of adapting to the growing needs of both patients and health funders. He highlighted the significance of embedding treatment programs within accredited clinical environments, allowing the company to deliver scalable, evidence-based mental health care that meets both patient needs and institutional expectations.
At 10:25 AEST, shares of Emyria Ltd (EMD) were trading at 3 cents, reflecting a 3.45% increase from market open. This market activity underscores the growing investor interest in the company’s strategic direction and its innovative approach to mental health care.
With its commitment to clinical excellence and accessible treatment models, Emyria continues to reinforce its role as a leading innovator in the evolving landscape of mental health services in Australia.
